

Pending Claims:

1. [Original] A purified complex comprising endotoxin bound to MD-2.
2. [Original] The complex of claim 1, wherein the endotoxin is a wild-type endotoxin.
3. [Original] The complex of claim 1, wherein the endotoxin is a gram-negative bacterial endotoxin.
4. [Original] The complex of claim 3, wherein the gram-negative bacterium is a *Neisseria*, *Escherichia*, *Pseudomonas*, *Haemophilus*, *Salmonella*, or *Francisella* bacterium.
5. [Original] The complex of claim 4, wherein the gram-negative bacterium is *Neisseria meningitidis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Salmonella typhimurium*, or *Francisella tularensis*.
6. [Original] The complex of claim 1 having a molecular weight of about 25,000.
7. [Original] The complex of claim 1, wherein the complex consists essentially of one molecule of endotoxin bound to one molecule of MD-2.
8. [Original] The complex of claim 1, wherein the complex is soluble in water.
9. [Original] The complex of claim 1, wherein the complex binds to TLR4.
10. [Original] The complex of claim 1, wherein the complex produces TLR4-dependent activation of cells.
11. [Original] The complex of claim 10, wherein the complex produces a half maximal TLR4-dependent activation of cells at a concentration of less than 1 nM of the complex.

12. [Original] The complex of claim 11, wherein the complex produces a half maximal TLR4-dependent activation of cells at a concentration of about 30 pM or less of the complex.
13. [Original] The complex of claim 1, wherein the endotoxin is hexa-acylated.
14. [Original] The complex of claim 1, wherein the endotoxin is an under-acylated endotoxin.
15. [Original] The complex of claim 14, wherein the endotoxin is a tetra-acylated endotoxin.
16. [Original] The complex of claim 14, wherein the endotoxin is a penta-acylated endotoxin.
17. [Original] The complex of claim 14, wherein the complex produces less TLR4-dependent activation of cells as compared to a complex comprising an endotoxin that is hexa-acylated.
18. [Original] A composition comprising the complex of claim 1.
19. [Original] The composition of claim 17, further comprising a pharmaceutically acceptable carrier.